TOMM40 Genotype

If you carry an APOE ε4 allele, you already know one part of your inherited story for Alzheimer's disease. The TOMM40 (translocase of outer mitochondrial membrane 40) gene sits right next to APOE on chromosome 19, and the length of a repeating DNA segment inside it may shift your risk and the age your symptoms might begin, even among people who share the same APOE result. TOMM40 genotyping is currently a research tool and is not endorsed by major clinical guidelines for Alzheimer's risk stratification.

This is a once-in-a-lifetime test that helps explain why two people with identical APOE genotypes can age differently. Researchers have used it alongside APOE in risk algorithms and in prevention research (most notably the TOMMORROW trial, which was stopped early after its primary intervention failed to show benefit), and it is the kind of result that becomes more useful the earlier you have it on file.

What This Gene Actually Does

TOMM40 codes for a protein that sits in the outer wall of your cells' energy compartments (the mitochondria) and helps import other proteins inside. The test does not measure that protein. Instead, it looks at the length of a repeating stretch of DNA called the '523' or poly-T variant. Labs group people into Short (S, 19 or fewer repeats), Long (L, 20 to 29 repeats), and Very Long (VL, 30 or more repeats) categories.

Because TOMM40 sits beside APOE, the two genes are usually inherited together as a haplotype. In European-ancestry populations, most APOE ε4 alleles travel with a Long TOMM40 variant, most ε3 alleles travel with Short or Very Long, and most ε2 alleles travel with Very Long. These linkage patterns are population-specific and look different in other ancestral backgrounds. For example, in African Americans only about 48% of ε4 carriers have the Long TOMM40 allele, compared with roughly 94% in people of European ancestry. The two results are most informative when read together.

Alzheimer's Disease Risk

The clearest signal for TOMM40 is in late-onset Alzheimer's disease, particularly in people who carry APOE ε3/ε3 and might otherwise assume they are at average risk. In a study of 1,170 older adults with the ε3/ε3 genotype, the Short/Short TOMM40 poly-T genotype was linked to faster cognitive decline, especially in episodic and semantic memory. A separate, smaller imaging study of 117 middle-aged ε3/ε3 individuals found that those with Very Long poly-T lengths showed early gray matter and cognitive changes consistent with presymptomatic Alzheimer's biology.

A study of 892 participants reported that the Long allele increased the risk of late-onset Alzheimer's disease when ε4 was absent. In a separate cohort of 2,388 Caucasian and African American older adults, the ε4-'523-L haplotype carried a stronger effect on Alzheimer's disease risk in African Americans than other ε4-'523 haplotypes. A pooled analysis of 24,122 participants concluded that APOE-TOMM40-APOC1 variants together play a defining role in Alzheimer's risk, with the largest excesses in ε4 carriers who also carry minor alleles at rs2075650 and rs12721046.

In 354 people followed for conversion from mild cognitive impairment to Alzheimer's disease, the APOE ε4-TOMM40 Long haplotype was linked to higher risk and shorter time to conversion. Imaging studies show the same haplotype is associated with early Alzheimer's-specific differences in cortical shape and thickness, even in people who are still cognitively healthy.

Reconciling Long vs Short Findings

You may notice that some studies flag Long alleles as risky, while others flag Short alleles, and that ancestry matters. This is not a contradiction in the data. TOMM40 is a phenotype indicator, not a simple good number, bad number marker. The same poly-T length can sit on different APOE backgrounds in different populations, and a study of local genetic ancestry showed that increasing poly-T length on the European ε3 background was actually associated with reduced Alzheimer's risk. Your result is most meaningful when interpreted alongside your APOE genotype and your ancestral background, not in isolation.

Other Conditions Linked to TOMM40

In Parkinson's disease, TOMM40 does not appear to change whether you get the disease. A study of 1,056 people found no link to Parkinson's risk, and although the variant appeared to shift age of symptom onset, that signal did not hold up after adjusting for other factors. A separate analysis of 368 people with Parkinson's disease reported that allele length predicted cognitive trajectory: shorter alleles tracked with more severe cognitive decline, and longer alleles tracked with preserved cognition and slower progression to dementia.

In dementia with Lewy bodies, an analysis of 451 brains tied APOE ε4 and Long TOMM40 alleles to higher susceptibility and earlier onset, with concurrent Alzheimer's pathology helping to explain the link. In 276 people with advanced atherosclerosis, the rs2075650 variant was associated with more fatal cardiovascular events and more left bundle branch block (a heart conduction problem). The same study saw a trend toward earlier pacemaker or defibrillator placement; this reached statistical significance only when enrollment and follow-up data were combined, and was not significant for new device implantations during follow-up alone. And in 169 older trauma patients, rs2075650 was linked to longer time on a ventilator and distinct inflammatory patterns.

Longevity Signals

TOMM40 variants also show up in healthy aging studies. In 5,480 Han Chinese adults, variants in the PVRL2-TOMM40-APOE region were associated with reaching very old ages. A pooled analysis concluded that APOE ε4 and TOMM40-APOC1 variants jointly contribute to surviving to older ages, with TOMM40-APOC1 effects strongest in carriers of the minor alleles. A systematic review identified rs2075650 and rs10524523 as the two TOMM40 variants most consistently linked to healthy aging and longevity, with effects spanning brain integrity, cognitive function, BMI, and vascular risk.

How TOMM40 Compares to APOE Alone

A risk algorithm combining APOE, TOMM40, and age in 1,067 participants showed sensitivity of 0.60 and specificity of 0.81 in one cohort and sensitivity of 0.65 and specificity of 0.61 in a second, with odds ratios of roughly 3 to 5 compared with APOE plus age alone. The same algorithm's high and low risk categories tracked well with cerebrospinal fluid markers and amyloid PET imaging. The takeaway is that TOMM40 adds some information beyond APOE, but the incremental gain is modest, and it is not a stand-alone diagnostic. It refines your risk picture, especially within APOE groups that would otherwise look uniform.

How to Interpret Your One-Time Result

Your TOMM40 result is set at conception and does not change. There is no reason to repeat the test once you have a confirmed call, and there is no useful trend to track in the result itself. The value is in how it shapes the rest of your monitoring plan over the years ahead.

What does change over time is the biology downstream of your genotype: cognitive performance, brain imaging, blood-based Alzheimer's markers, and cardiovascular risk factors. If you carry a higher-risk APOE-TOMM40 haplotype, those companion measures are the things worth tracking on a regular cadence, not your TOMM40 result. A reasonable rhythm is annual cognitive testing and an annual review of vascular risk markers starting in midlife, with closer follow-up if you also have a family history of dementia. Keep in mind that no guideline currently endorses TOMM40 results as a basis for these decisions, so they are best made together with your clinician.

What Your Result Should Make You Do Next

If your result places you in a higher-risk haplotype, the productive next step is not more genetic testing. It is to use that information to drive earlier and more attentive monitoring of the things that actually move with age. That means an APOE genotype if you do not already have one, a baseline cognitive assessment to compare future testing against, and a careful look at vascular risk factors, since cardiovascular health is one of the strongest modifiable contributors to dementia risk.

Consider a referral to a genetic counselor or a memory specialist if your result is high risk and you have a strong family history, if you are weighing decisions like long-term care planning, or if you want help interpreting the result alongside emerging blood-based Alzheimer's biomarkers. Sharing the result with biological relatives is also a reasonable conversation, since the same variant can sit in siblings, children, and parents.

When Results Can Be Misleading

• Variant panel coverage: the assay reports the specific TOMM40 variants it is designed to detect, usually the '523' poly-T length and a small number of single-letter variants. A typical report does not rule out other rare changes in the gene.
• Ancestry effects: the same allele can carry different risk weights in different ancestral backgrounds. A Long allele on a European ε3 background appears to lower Alzheimer's risk, while the same allele on an African ε4 background appears to raise it.
• Confusion with APOE: TOMM40 is not the same test as APOE. The two sit next to each other and are usually inherited together, but they are reported separately, and a TOMM40 result does not substitute for knowing your APOE genotype.
• Direct-to-consumer reports: some consumer reports include TOMM40 SNPs but not the '523' poly-T length, which is the variant most studied for Alzheimer's risk. A clinical-grade assay that specifically genotypes the poly-T length gives a different and more useful result.

Penetrance and What a Risk Variant Really Means

Carrying a higher-risk TOMM40 variant does not mean you will develop Alzheimer's disease or any other condition. It shifts your odds. Plenty of people with the highest-risk haplotypes live into their nineties with intact cognition, and plenty of people with low-risk haplotypes still develop dementia. The result is a probability statement about your future, not a diagnosis or a fate.